Mitochondria, Autophagy and Neurodegenerative diseases: A perspective
Review paper from University of Helsinki looks at the role of mitophagy in ageing
Mitochondria
Known as “the powerhouse of the cell”, mitochondria generate most of the cell’s supply of adenosine triphosphate (ATP) which transports chemical energy within cells for metabolism. They are membrane-bound organelle found in most eukaryotic cells.
Resources
Click on resource name for more details.
Stealth BioTherapeutics
Biopharmaceutical company focused on the discovery and commercialization of novel therapies..
Cellvie
Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell
Mitochondria, Aging, and Health
08-Jan-2021
Speakers are Douglas Wallace, Francesca Fieni, Hazel Szeto and Michael Zemel
Pano Therapeutics
Addressing complex diseases of aging by targeting mitochondrial ion channels and transporters.
Mitochondria Blog Posts
23-Nov-2022
Recent News
Mitochondria boosting therapy rejuvenates immune system of mice
Longevity Technology - 11-Oct-2022
If successful in humans it would improve the outcome of many age-related diseases
Read more...Longevity Technology interviews cellvie CEO, Alex Schueller, about therapeutic mitochondria
Longevity Technology - 14-Sep-2022
Initially targeting ischemia-reperfusion injury, TMT has potential to treat multiple age-related diseases
Read more...$72m funding launching Pretzel Therapeutics pioneering mitochondrial therapies
Biospace - 12-Sep-2022
Pretzel targets genome correction, genome expression modulation and mitochondrial quality control
Read more...Restructured mitochondrial metabolism linked to survival of human eggs
STAT - 20-Jul-2022
Complex I production temporarily halted in quiescent oocytes, promoting fertility
Read more...MitoRx Therapeutics' CEO shares insights on fundraising and pitching to investors
UK Innovation & Science Seed Fund - 20-Jul-2022
Effectively communicating to investors will translate an ideology into a social benefit
Read more...
